Deciphera Pharmaceuticals (DCPH) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a hold rating to a buy rating in a research note published on Tuesday. Zacks Investment Research currently has $28.00 price target on the stock.

According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “

A number of other brokerages also recently issued reports on DCPH. Instinet began coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued a buy rating and a $57.00 price objective on the stock. BidaskClub upgraded Deciphera Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday. Nomura began coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set a buy rating and a $57.00 price target on the stock. JMP Securities began coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an outperform rating and a $38.00 price target on the stock. Finally, JPMorgan Chase & Co. began coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an overweight rating and a $30.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, The stock has an average rating of Buy and an average price target of $40.83.

Shares of Deciphera Pharmaceuticals (DCPH) traded up $0.59 during mid-day trading on Tuesday, hitting $25.66. The company had a trading volume of 134,562 shares, compared to its average volume of 185,686. Deciphera Pharmaceuticals has a one year low of $15.15 and a one year high of $26.59. The stock has a market capitalization of $820.98 and a P/E ratio of -6.48.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings data on Tuesday, November 14th. The company reported ($5.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($5.30). research analysts expect that Deciphera Pharmaceuticals will post -2.91 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DCPH. Orbimed Advisors LLC purchased a new stake in Deciphera Pharmaceuticals during the third quarter valued at about $7,487,000. Emerald Advisers Inc. PA purchased a new stake in Deciphera Pharmaceuticals during the third quarter valued at about $6,661,000. Emerald Mutual Fund Advisers Trust purchased a new stake in Deciphera Pharmaceuticals during the third quarter valued at about $5,548,000. Citadel Advisors LLC purchased a new stake in Deciphera Pharmaceuticals during the third quarter valued at about $4,965,000. Finally, Kornitzer Capital Management Inc. KS purchased a new stake in Deciphera Pharmaceuticals during the third quarter valued at about $2,172,000. Institutional investors and hedge funds own 43.94% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Deciphera Pharmaceuticals (DCPH) Stock Rating Upgraded by Zacks Investment Research” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2018/01/11/deciphera-pharmaceuticals-dcph-stock-rating-upgraded-by-zacks-investment-research.html.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply